Summary
Dee McCaffrey, an organic chemist and nutritionist, examines the history and current evidence for high-dose vitamin C as a cancer treatment. She traces the research from Linus Pauling and Ewan Cameron's successful 1970s studies combining IV and oral vitamin C for cancer patients, through the Mayo Clinic's failed replication attempts in the 1980s that used only oral vitamin C, to modern clinical trials showing renewed promise. The critical finding discussed is that IV vitamin C achieves blood levels roughly 100 times higher than equivalent oral doses, explaining why the Mayo Clinic studies failed to replicate the earlier results. Recent research from Cornell, Tufts, Harvard, and Johns Hopkins showed that high-dose vitamin C equivalent to 300 oranges (about 21,000 mg IV) impaired growth of mutant colorectal tumors that were previously resistant to other cancer treatments. Unlike chemotherapy, vitamin C selectively targets cancer cells without destroying healthy tissue, meaning patients don't experience hair loss or typical chemo side effects.
Key Points
- Linus Pauling and Ewan Cameron reported success treating about 50 cancer cases with combined IV and oral vitamin C in the 1970s
- The Mayo Clinic's 1980s studies failed to replicate these results because they used only oral vitamin C instead of IV
- IV vitamin C achieves blood levels approximately 100 times higher than equivalent oral doses
- A 2015 multi-center study (Cornell, Tufts, Harvard, Johns Hopkins) found high-dose IV vitamin C impaired growth of mutant colorectal tumors
- The therapeutic dose equivalent is roughly 300 oranges worth of vitamin C (about 21,000 mg) delivered intravenously
- IV vitamin C combined with chemotherapy is extending survival in pancreatic and ovarian cancer patients
- Unlike chemotherapy, vitamin C selectively targets cancer cells without destroying healthy tissue
- Genetic testing may predict which patients will respond to vitamin C therapy based on specific tumor mutations
Key Moments
Mayo Clinic used wrong protocol when testing vitamin C for cancer
Dee explains that the Mayo Clinic studies in the 1980s failed to replicate the 1970s results because they only gave vitamin C orally instead of intravenously, a critical methodological difference that dampened enthusiasm for the therapy for decades.
"were actually not, they weren't the same. Like they didn't do the same protocols that they did in the 70s. And so now there's new interest and new studies that are being done using vitamin C therapy. And we're finding that it's working. Wow, that's great. Okay. So just to kind of give a little bit of the history."
IV vitamin C achieves 100x higher blood levels than oral
The episode reveals that intravenous vitamin C produces blood levels approximately 100 times higher than equivalent oral doses, because oral absorption is limited by intestinal transport mechanisms.
"you get about 100 times more blood level of vitamin C when it is intravenous. And that makes sense, of course, right? Because it bypasses all of the the intestinal travel that that has to go through."
Multi-center study shows vitamin C kills treatment-resistant colorectal tumors
A 2015 study from Cornell, Tufts, Harvard, and Johns Hopkins found that high-dose IV vitamin C equivalent to 300 oranges impaired growth of mutant colorectal tumors that had been previously resistant to all other cancer treatments.
"roughly the equivalent to the level found in 300 oranges, basically impaired the growth of mutant colorectal tumors. And by the way, these types of tumors had been previously resistant to any other kind of cancer treatments. Oh, no kidding. Yeah. So they're finding that this vitamin C therapy is,"
Vitamin C selectively targets cancer cells unlike chemotherapy
Unlike chemotherapy which kills both cancer and healthy cells, vitamin C therapy selectively targets cancer cells, meaning patients don't lose hair or experience typical chemo side effects.
"With chemotherapy, a lot of times it kills the cancer cells, but it also kills off a lot of the healthy cells as well. Whereas vitamin C only targets the cancer cells and not the, you know, healthy cells."
